Evidence map›Paper›PMID 40620311›Full record

ArticlePrzeglad gastroenterologiczny2025

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and endoscopic ultrasound-guided ethanol ablation (EUS-EA) of pancreatic neuroendocrine tumors and adenocarcinoma: a prospective multicenter study.

Hussein H Okasha, Ahmed Y Altonbary, Khaled Ragab, Elsayed Ghoneem, Mohammed Tag-Adeen, Abeer Abdellatef, Mohammed S Naguib, Bogdan Miutescu, Eyad Gadour

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Przeglad gastroenterologiczny, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hussein H OkashaDepartment of Internal Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Cairo University, Cairo, Egypt.
Ahmed Y AltonbaryDepartment of Gastroenterology and Hepatology, Mansoura University, Mansoura, Egypt.
Khaled RagabDepartment of Hepatology and Gastroenterology, Theodor Bilharz Research Institute, Giza, Egypt.
Elsayed GhoneemDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohammed Tag-AdeenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Qena Faculty of Medicine, South Valley University, Qena, Egypt.
Abeer AbdellatefDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, Kasr Al-Aini School of Medicine, Cairo University, Cairo, Egypt.
Mohammed S NaguibDepartment of Gastroenterology, Ahmed Maher Teaching Hospital, Cairo, Egypt.
Bogdan MiutescuDepartment of Gastroenterology and Hepatology Victor Babes" University of Medicine and Pharmacy University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania.
Eyad GadourMultiorgan Transplant Centre of Excellence, Liver Transplantation Unit, King Fahad Specialist Hospital, Damma, Suadi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and endoscopic ultrasound-guided ethanol ablation (EUS-EA) are emerging novel methods for managing non-functioning and functioning pNET and adenocarcinoma in the pancreas. Aim: To assess the safety profile, feasibility, and outcomes of EUS-RFA and EUS-EA of focal pancreatic masses. Material and methods: This prospective study included 27 patients, 15 males and 12 females, with a mean age of 36.38 years. EUS-RFA was carried out in 13 patients; 11 had pancreatic insulinoma, and 2 had advanced pancreatic adenocarcinoma. The mean size of the masses was 20.6 mm, while that of the insulinomas was 17.4 mm. The median number of needle passes was 3, with a range of 1 to 6. RFA was conducted using 19G EUSRA needles from Taewoong Co., Ltd., South Korea. No minor or major complications were observed. EUS-EA was carried out in 14 patients, all of whom had pancreatic insulinoma. The mean size of the masses was 15.3 mm. The median number of needle passes was 2, with a range of 1 to 3. We used 19G and 22G echo tip FNA needles from Cook Company, USA. The mean duration of follow-up was 12.4 months. There was mild to moderate acute pancreatitis in 4 patients in the EUS-EA group; all were relieved by conservative therapy, and no hospital admission was required. No early or late significant complications were reported in the EUS-RFA group. Results: There was a complete clinical cure of 10 out of 11 (91%) patients with pancreatic insulinoma who underwent EUS-RFA. However, 1 patient required three sessions, and 2 patients required two sessions of EUS-RFA. The 11 Conclusions: EUS-RFA and EUS-EA can potentially treat lesions and control symptoms. EUS-RFA is a more promising and safer technique for managing functioning insulinomas. However, it cannot downstage pancreatic ductal adenocarcinoma patients. EUS-EA seems less efficient, with more adverse events than EUS-RFA.

Indexed as

endoscopic ultrasound-guided ethanol ablationendoscopic ultrasound-guided radiofrequency ablationEUS-RFAinsulinomapancreatic neuroendocrine tumors

Identifiers

PMID40620311
PMCPMC12224237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.